Patients
LIVER METASTASES, GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
We screened 3001 GEJA patients newly diagnosed between 2010 and 2015 from the SEER database who met our inclusion criteria, of which 281 developed liver metastases. The exclusion process is shown in Fig. Patient screening flowchart. This figure contains how we screened 3001 Siewert type II gastroesophageal junction adenocarcinoma patients from the SEER database.